Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Mulling Whether To Add Unannounced Inspections To Drug Safety Arsenal In China

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - U.S. FDA's newly launched China office is still developing protocols for the country, and the agency is considering adding the use of unannounced inspections to its arsenal of tools crafted to improve product safety and quality

You may also be interested in...



EU Proposed Regulation Raises Concerns From China’s API Exporters

EU draft guidance calls for greater clarity on the source of API, putting many Chinese manufacturers in a tough position.

SFDA Revises China GMP Guidelines; Seeks Industry Comments On Impact To Local Industry

SHANGHAI - China's State FDA revised its Good Manufacturing Practices Guidelines, and is asking for industry feedback on how the guidelines would affect local pharmaceutical companies, SFDA Deputy Director Wu Zhen said during a forum on drug safety and healthcare reform in Beijing April 28

U.S. FDA Launches First Overseas Office in Beijing

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

Related Content

UsernamePublicRestriction

Register

ID1131511

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel